- All sections
- A - Human necessities
- A61K - Preparations for medical, dental or toiletry purposes
- A61K 31/4245 - Oxadiazoles
Patent holdings for IPC class A61K 31/4245
Total number of patents in this class: 2607
10-year publication summary
|
153
|
190
|
217
|
193
|
168
|
166
|
144
|
171
|
183
|
109
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Bristol-myers Squibb Company | 4748 |
45 |
| Merck Sharp & Dohme LLC | 3736 |
44 |
| Novartis AG | 10178 |
40 |
| F. Hoffmann-La Roche AG | 7815 |
31 |
| Chong Kun Dang Pharmaceutical Corp. | 249 |
31 |
| Takeda Pharmaceutical Company Limited | 2712 |
30 |
| PTC Therapeutics, Inc. | 473 |
30 |
| Aurigene Oncology Limited | 128 |
30 |
| Cytokinetics, Inc. | 251 |
26 |
| Daiichi Sankyo Company, Limited | 1891 |
23 |
| The Scripps Research Institute | 1346 |
23 |
| Hoffmann-La Roche Inc. | 3815 |
21 |
| Boehringer Ingelheim International GmbH | 4483 |
19 |
| Astellas Pharma Inc. | 1039 |
19 |
| Taisho Pharmaceutical Co., Ltd. | 850 |
19 |
| Merck Patent GmbH | 5735 |
18 |
| Receptos LLC | 61 |
18 |
| Stealth Biotherapeutics Inc. | 194 |
17 |
| Glaxo Group Limited | 4375 |
16 |
| Allergan, Inc. | 2159 |
16 |
| Other owners | 2091 |